Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 30 · below the Ichimoku cloud · RSI 46 · MACD above its signal
None of the 29 investors followed here reported a position in FAMDF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FAMDF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Unitt (Andrew Vaughan) | Increase at price 0.26 per share. | 6.00M | $1.59M |
| Sep 24, 2026 | James (Ken W) | — | 2.50M | — |
| Sep 24, 2026 | Kevin & Patrick Byrne | — | 0 | — |
| Sep 24, 2026 | Mcalpine (R) | — | 50.00M | — |
| Sep 24, 2026 | Morton (Robert) | — | 0 | — |
| Sep 24, 2026 | Philip J Milton & Co Plc | — | 8.91M | — |
| Sep 24, 2026 | Simon & Sandra Gibeon | — | 0 | — |
| Sep 24, 2026 | Tracarta, Ltd. | — | 0 | — |
| Sep 24, 2026 | Burton (Nigel) | — | 0 | — |
| Sep 24, 2026 | Cantor Fitzgerald Europe | — | 14.52M | — |
| Sep 24, 2026 | Cottrell (Kathryn) | — | 0 | — |
| Sep 24, 2026 | Davis (Roy J Jr) | — | 2.50M | — |
| Sep 24, 2026 | Duggan (Alexander James Hanbury) | — | 12.50M | — |
| Sep 24, 2026 | First Equity Limited | Bought at price 0.00 per share. | 46.38M | — |
| Sep 24, 2026 | Hawkins (Nigel) | — | 0 | — |
| Sep 23, 2026 | Alvar Financial Services Ltd | — | 0 | — |
| Sep 22, 2026 | Tracarta, Ltd. | — | 50.00M | — |
| Sep 20, 2026 | Ribas (Jose) | — | 0 | — |
| Sep 20, 2026 | Adams (Terence) | — | 0 | — |
| Sep 17, 2026 | Nyunt Tin And Family | Sold at price 0.27 per share. | 2.22M | $593.74K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 52.7 | -38.1 | -7.7 | 8.3 | -50.0 | 7.7 | -42.9 | -37.5 | 60.0 | -35.0 | −81.1% | ||
| 2025 | -44.7 | -28.1 | -0.7 | -36.7 | 36.8 | -25.0 | 64.1 | -31.2 | -54.5 | -37.2 | -52.2 | -8.3 | −96.4% |
| 2024 | 11.4 | 35.9 | -5.7 | -16.0 | 11.9 | -4.0 | -11.3 | 5.0 | 7.1 | 8.9 | -4.1 | -19.1 | +8.6% |
| 2023 | -27.4 | 66.7 | -20.0 | 3.3 | -1.6 | 29.5 | -7.6 | -11.0 | -20.0 | -33.1 | 12.1 | -10.3 | −43.5% |
| 2022 | 88.7 | -56.5 | -26.4 | 12.5 | 2.8 | 0.0 | -2.7 | 63.9 | -13.4 | 76.1 | -43.9 | 22.8 | +17.0% |
| 2021 | 0.0 | 24.3 | 223.9 | -6.0 | 42.9 | -37.0 | -11.1 | 7.1 | 66.7 | -47.0 | 0.0 | 0.0 | +186.5% |
| 2020 | 26.7 | -31.6 | 0.0 | 0.0 | 107.7 | -1.9 | -47.2 | 53.9 | 2.1 | -31.8 | 40.0 | -11.9 | +23.3% |
| 2019 | 162.0 | 0.0 | 87.0 | 0.0 | 22.4 | 33.7 | 23.4 | 5.1 | -18.3 | -19.8 | 0.0 | -56.0 | +200.0% |
| 2018 | 60.0 | -10.7 | 0.0 | -10.0 | 0.0 | -3.3 | -3.4 | 0.0 | -14.3 | -56.9 | -39.3 | -44.4 | −85.1% |
| 2017 | 0.0 | 0.0 | 3.9 | -0.9 | 0.0 | 0.0 | 0.0 | 0.0 | -50.7 | 0.0 | 2.9 | 0.0 | −47.8% |
| 2016 | -6.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.2 | 152.2 | 0.0 | -13.8 | -10.7 | +65.4% |
| 2015 | 0.0 | -24.4 | 0.0 | 25.2 | 14.4 | -19.7 | 0.0 | 0.0 | -19.2 | -2.3 | -21.1 | 22.7 | −33.6% |
| 2014 | -0.5 | 0.9 | -4.6 | 9.7 | -7.5 | -4.3 | -11.0 | -10.1 | -0.4 | -26.0 | 3.4 | 0.0 | −43.3% |
| 2013 | 12.1 | 3.9 | -9.4 | 20.8 | 1.7 | -8.5 | -0.9 | -1.9 | 2.9 | -4.6 | -12.6 | 19.4 | +18.1% |
| 2012 | 30.0 | 2.6 | -15.2 | 16.5 | -6.8 | 0.0 | -23.8 | -49.1 | 0.0 | 58.1 | 0.0 | -1.6 | −26.0% |
| 2011 | 0.0 | 22.3 | 0.0 | -10.9 | 13.1 | -5.7 | 9.9 | -13.3 | -23.4 | 10.5 | 0.0 | 17.1 | +9.8% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 83.6 | +83.6% |
| 2009 | 0.0 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.